« Back
Home /
Urokinase (PLAU) Antibody (C-term) Blocking peptide

Urokinase (PLAU) Antibody (C-term) Blocking peptide

Item no.	ABC-BP8161b
Manufacturer	Abcepta
Amount	500 ug
Category	Oncology Peptides & Proteins Peptides By Organ Breast Cancer
Type	Peptides
Format	Lyophilized
Specific against	other
Citations	Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002).Sperl, S., et al., Proc. Natl. Acad. Sci. U.S.A. 97(10):5113-5118 (2000).Turkmen, B., et al., Electrophoresis 18(5):686-689 (1997).Conne, B., et al., Thromb. Haemost. 77(3):434-435 (1997).Yoshimoto, M., et al., Biochim. Biophys. Acta 1293(1):83-89 (1996).
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	Urokinase-type plasminogen activator,U-plasminogen activator,uPA,Urokinase-type plasminogen activator long chain A,Urokinase-type plasminogen activator short chain A,Urokinase-type plasminogen activator chain B,PLAU
Similar products	uPA, PLAU, Urokinase-type plasminogen activator, Urokinase-type plasminogen activator long chain A, Urokinase-type plasminogen activator short chain A, Urokinase-type plasminogen activator chain B, U-plasminogen activator
Available
Manufacturer - Category	Peptides; Blocking Peptides
Manufacturer - Targets	The synthetic peptide sequence used to generate the antibody AP8161b was selected from the C-term region of human PLAU. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Bio Background	PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-\|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
Gene Name	PLAU
Subtitle	Synthetic peptide
Formulation	Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

ABC-BP8161b-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 500 ug

available

Delivery expected until 11/6/2025

Express Delivery: Save 14 days

Compare

Add to wishlist

Get an offer